Scynexis INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
SCYX
Scynexis INCSCYNEXIS, Inc. reported a net loss of $8.6 million for FY2025, terminated the MARIO study with GSK for a $24.8 million payment, and is advancing its second-generation antifungal SCY-247 into Phase 1 IV and Phase 2 oral trials.
NASDAQ
SCYX
Scynexis INCSCYNEXIS's 2024 results highlight a year of transition, marked by a BREXAFEMME recall, progress in clinical development, and strategic focus on antifungal innovation.
NASDAQ
SCYX
Scynexis INC10-K: Scynexis and GSK Amend License Agreement Following Manufacturing Issue, Adjusting Milestone Payments
Scynexis and GlaxoSmithKline have amended their exclusive license agreement for ibrexafungerp, adjusting milestone payments and responsibilities following a manufacturing issue that led to a product recall and clinical hold.